Search
Now showing items 1-10 of 29
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial.
(2021-01-23)
BACKGROUND: Although targeted biological treatments have transformed the outlook for patients with rheumatoid arthritis, 40% of patients show poor clinical response, which is mechanistically still unexplained. Because more ...
B CELL-RICH SYNOVITIS IN EARLY AND ESTABLISHED RHEUMATOID ARTHRITIS
(2020-04)
Meeting abstract P233 from British Society for Rheumatology Annual Conference 2020
The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts' Consensus.
(2021-02)
Autoimmune diseases (AIDs) share similar serological, clinical, and radiological findings, but, behind these common features, there are different pathogenic mechanisms, immune cells dysfunctions, and targeted organs. In ...
Impaired IL‐27 Mediated Control of CD4+ T Cell Function Impacts on Ectopic Lymphoid Structure Formation in Patients with Sjögren's Syndrome
(Wiley, 2020-04-20)
This is the pre-peer reviewed version of the following article: Lucchesi, D., Coleby, R., Pontarini, E., Prediletto, E., Rivellese, F., Hill, D.G., Derrac Soria, A., Jones, S.A., Humphreys, I.R., Sutcliffe, N., Tappuni, ...
Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study
(Elsevier, 2020-01-23)
© 2020 Elsevier Ltd Background: Primary Sjögren's syndrome is an autoimmune disease that presents as dryness of the mouth and eyes due to impairment of the exocrine glands. To our knowledge, no systemic therapies for primary ...